This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

AstraZeneca Dividenden en inkoop

Dividend criteriumcontroles 4/6

AstraZeneca is een dividendbetalend bedrijf met een huidig rendement van 1.66% dat ruimschoots wordt gedekt door de winst.

Belangrijke informatie

1.7%

Dividendrendement

0.2%

Terugkoop Rendement

Totaal aandeelhoudersrendement	1.8%
Toekomstig dividendrendement	1.9%
Dividendgroei	0.9%
Volgende betaaldatum dividend	n/a
Ex-dividenddatum	n/a
Dividend per aandeel	n/a
Uitbetalingsratio	52%

Recente updates van dividend en inkoop

Geen updates

Recent updates

Seeking Alpha • Jan 10

AstraZeneca: Oncology Dominance Justifies New All-Time Highs

Summary AstraZeneca started 2026 on a high note. On January 7, its stock reached an all-time high of $95.94. The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular franchises. For example, sales of Tagrisso, an EGFR inhibitor for the treatment of people with non-small cell lung cancer, reached $1.86 billion in Q3, up 11.4% year-on-year. And coupledwith significant progress in its baxdrostat and blockbuster therapy Imfinzi, Icontinue to cover AstraZeneca with a 'Buy' rating. Read the full article on Seeking Alpha

Seeking Alpha • Mar 05

AstraZeneca: A Big Pharma Blue Chip To Buy Now

Summary AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. The company is well-positioned for growth over the next few years. AstraZeneca's net debt-to-adjusted EBITDA ratio improved to just 1.5x in 2024. Shares of the drugmaker appear to be priced 14% below fair value. AstraZeneca could be set up to generate 15% annual total returns through 2027. Read the full article on Seeking Alpha

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: De dividendbetalingen van AZN zijn de afgelopen 10 jaar volatiel geweest.

Groeiend dividend: De dividendbetalingen van AZN zijn de afgelopen 10 jaar gestegen.

Dividendrendement versus markt

AstraZeneca Dividendrendement versus markt

Hoe verhoudt AZN dividendrendement zich tot de markt?
Segment	Dividendrendement
Bedrijf (AZN)	1.7%
Markt onderkant 25% (US)	1.4%
Markt Top 25% (US)	4.3%
Gemiddelde industrie (Pharmaceuticals)	2.1%
Analist prognose (AZN) (tot 3 jaar)	1.9%

Opmerkelijk dividend: Het dividend van AZN ( 1.66% ) is hoger dan dat van de onderste 25% van de dividendbetalers op de US markt ( 1.44% ).

Hoog dividend: Het dividend AZN ( 1.66% ) is laag vergeleken met de top 25% van dividendbetalers in de US markt ( 4.32% ).

Winstuitkering aan aandeelhouders

Verdiendekking: Met zijn redelijke payout ratio ( 51.6% ) worden de dividendbetalingen van AZN gedekt door de winst.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: Met zijn redelijke cash payout ratio ( 51% ) worden de dividendbetalingen van AZN gedekt door kasstromen.

Ontdek bedrijven met een sterk dividend

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/02/03 03:29
Aandelenkoers aan het einde van de dag	2026/01/30 00:00
Inkomsten	2025/09/30
Jaarlijkse inkomsten	2024/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

AstraZeneca PLC wordt gevolgd door 60 analisten. 24 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
null null	ABG Sundal Collier
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research

This company listing is no longer active

AstraZeneca Dividenden en inkoop

Dividend criteriumcontroles 4/6

Belangrijke informatie

Recente updates van dividend en inkoop

Recent updates

AstraZeneca PLC (LSE:AZN) agreed to acquire remaining 50% stake in China rights to GPC3 armored CAR-T therapy from Abelzeta Inc. for $630 million.

European Medicines Agency Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

AstraZeneca PLC (LSE:AZN) acquired Modella AI, Inc.

TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

AstraZeneca: Oncology Dominance Justifies New All-Time Highs

AstraZeneca Appoints Rick R. Suarez As Senior Vice President, US President, And Head Of US BioPharmaceuticals Business Unit

Astrazeneca and Enhertu Announce that it has Been Granted Breakthrough Therapy Designation in the US for Adult Patients with Her2-Positive Early Breast Cancer with Residual Invasive Disease in the Breast And/Or Axillary Lymph Nodes After Neoadjuvant Treatment and High Risk of Disease Recurrence

Daiichi Sankyo and AstraZeneca's DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy

Astrazeneca and Daiichi Sankyo's ENHERTU®? (Fam-Trastuzumab Deruxtecan-nxki) Approves in the US as First New Treatment in A decade for the 1st-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer

AstraZeneca PLC Advances Hematology and Cell Therapy Ambition with Largest-Ever Presence at ASH

AstraZeneca's New Drug Application Accepted Under FDA Priority Review in the US for Patients with Hard-To-Control Hypertension

AstraZeneca plc Announces Approval in the US for First and Only Perioperative Immunotherapy for Patients with Early Gastric and Gastroesophageal Cancers

Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib) Approves in the US

AstraZeneca Announces Positive Full Results from the Bax24 Phase III Trial

AstraZeneca PLC Reiterates Earnings Guidance for 2025

DESTINY-Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Small Cell Lung Cancer

AstraZeneca PLC Announces Koselugo Approved in the EUfor Plexiform Neurofibromas in Adults with Neurofibromatosis Type 1

AstraZeneca and Amgen's Tezepelumab Approves in the European Union

Daiichi Sankyo and AstraZeneca Announces Positive Results from the TROPION-Breast02 Phase 3 Trial

AstraZeneca and Amgen's Tezepelumab Approves in the US for Chronic Rhinosinusitis with Nasal Polyps

AstraZeneca, Inc. Announces Positive Results from the Matterorn Phase III Trial

AstraZeneca Furthers ambition to Redefine Cancer Care with First Data from Four Major Pivotal Trials at ESMO

AstraZeneca PLC Announces Baxdrostat Met Primary Endpoints in Bax24 Phase Iii Trial in Patients with Resistant Hypertension

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from the TROPION-Breast02 Phase III Trial

Daiichi Sankyo and Astrazeneca's Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk Her2 Positive Early-Stage Breast Cancer Prior to Surgery

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from Planned Interim Analysis of the DESTINY-Breast05 Phase III Trial

AstraZeneca Launches Direct-To-Consumer Platform to Expand Access to Medications for US Patients, Including Those Living with Chronic Conditions

Daiichi Sankyo and AstraZeneca's Supplemental Biologics License Application for Enhertu®? in Combination with Pertuzumab Deruxtecan-nxki

AstraZeneca PLC Announces European Medicines Agency Recommends Koselugo for the Treatment of Plexiform Neurofibromas in Adult Patients

AstraZeneca, Inc. Provides Update on A Supplemental New Drug Application (sNDA) for Airscra

AstraZeneca plc Announces Saphnelo Met Primary Endpoint in TULIP-SC

ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors

AstraZeneca Announces Positive Results from the Final Overall Survival Analysis of the FLAURA2 Phase III Trial

AstraZeneca Launches FluMist Home, At-Home Delivery Service for FLUMIST

Astrazeneca Canada Inc. Announces Approval in Canada as First and Only Perioperative Immunotherapy for Muscle Invasive Bladder Cancer

AstraZeneca PLC Reiterates Earnings Guidance for the Fiscal Year 2025

AstraZeneca PLC Announces Positive Results from PrevaIL Phase III Trial

AstraZeneca Announces Positive High-Level Results from the Final Overall Survival Analysis of the FLAURA2 Phase III Trial

Alexion Announces Update on CARES Phase III Clinical Programme of Anselamimab in Light Chain Amyloidosis

AstraZeneca plc Announces Baxdrostat Met the Primary and All Secondary Endpoints in BaxHTN Phase III Trial in Patients with Undunded or Treatment Resistant Hypertension

European Union Approves Imfinzi®? (Durvalumab) for the Treatment of Adult Patients with Resistant Muscle-Invasive Bladder Cancer

Datroway Approves in Us for EGFRm Lung Cancer

AstraZeneca plc Announces Fixed-Term Calquence Approval in EU for 1L CLL

AstraZeneca and Daiichi Sankyo’S ENHERTU Plus Pertuzumab Showed A Median Progression-Free Survival Greater Than Three Years

Astrazeneca's Imfinzi Recommends for Approval in the Eu by Chmp as First and Only Perioperative Immunotherapy for Muscle-Invasive Bladder Cancer

Health Canada Grants Notice of Compliance with Conditions for Tagrisso (Osimertinib) for the Treatment of Patients with Locally Advanced, Unresectable (Stage Iii) Non-Small Cell Lung Cancer

AstraZeneca 's Record Seventh Year of Plenary Data At Asco Furthers Ambition to Redefine Breast Cancer Care and Transform Outcomes in Gastric Cancer

AstraZeneca PLC (LSE:AZN) completed the acquisition of EsoBiotec B.V.

Astrazeneca to Showcase Latest Research on Comprehensive Portfolio and Pipeline Aimed At Transforming Respiratory Diseases At ATS 2025

AstraZeneca’s IMFINZI® (durvalumab) Regimen Demonstrates Statistically Significant and Clinically Meaningful Improvement in Disease-Free Survival for High-Risk Non-Muscle-Invasive Bladder Cancer in Potomac Phase III Trial

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from the DESTINY-Breast11 Phase III Trial

Astrazeneca Met Primary Endpoints in Kalos and Logos Phase Iii Trials in Asthma

AstraZeneca PLC to Report Q2, 2025 Results on Jul 29, 2025

Enhertu Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

AstraZeneca PLC Appoints Karen Knudsen as Director

Daiichi Sankyo and AstraZeneca Announce European Union Approves DATROWAY®? for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

AstraZeneca PLC Approves Imfinzi in Eu for AEGEAN

AstraZeneca’s AZD0780 Demonstrates Significant LDL Cholesterol (LDL-C) Reduction in Pursuit Phase IIb Trial

IgniteData Advances Clinical Trial Efficiencies with Successful Deployment at Leading Cancer Center

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca

AstraZeneca PLC Announces Eneboparatide Met Primary Endpoint of Normalising Seric Calypso Trial Continues as Planned to 52 Weeks to Further Characterise the Risk-Benef Benefit Profile

Ionis Pharmaceuticals, Inc. and Astrazeneca’s WAINZUA (eplontersen) Approves in the EU for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults with Stage 1 or Stage 2 Polyneuropathy

AstraZeneca PLC Announces Positive High-Level Results from the Matterhorn Phase III Trial